Advertisement

Management of No-Reflow

  • Danijela Trifunovic
  • Jelena Dudic
  • Natalija Gavrilovic
  • Olivia Manfrini
Chapter

Abstract

Despite considerable progress in percutaneous coronary interventions, the phenomenon of coronary no-reflow (NR) still represents a serious problem. It occurs when cardiac tissue fails to perfuse normally despite opening of the occluded vessel. The consequences of NR include infarct expansion, early congestive heart failure, ventricular arrhythmias and adverse left ventricular remodeling. All the actions that improve myocardial tissue perfusion should convert into a better prognosis and a better clinical outcome. The pathophysiology of NR is still not fully elucidated, and several mechanisms are proposed, with microvascular obstruction as the leading one. Despite considerable progress in the identification of the risks to NR development, no specific therapies have been developed so far. In this review, pharmacological and nonpharmacological interventions that might improve coronary blood flow are discussed.

Keywords

No-reflow Percutaneous coronary interventions ST-segment elevation myocardial infarction 

References

  1. 1.
    Kloner RA, Ganote CE, Jennings RB. The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974;54(6):1496–508.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Rezkalla SH, Stankowski RV, Hanna J, Kloner RA. Management of no-reflow phenomenon in the catheterization laboratory. JACC Cardiovasc Interv. 2017;10(3):215–23.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Berry C, Maznyczka AM, McCartney P. Failed myocardial reperfusion during primary PCI: an unmet therapeutic need. EuroIntervention. 2019;14(16):1628–30.PubMedCrossRefGoogle Scholar
  4. 4.
    Carrick D, Haig C, Ahmed N, et al. Myocardial hemorrhage after acute reperfused ST-segment-elevation myocardial infarction: relation to microvascular obstruction and prognostic significance. Circ Cardiovasc Imaging. 2016;9(1):e004148.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Bouleti C, Mewton N, Germain S. The no-reflow phenomenon: state of the art. Arch Cardiovasc Dis. 2015;108:661–74.CrossRefGoogle Scholar
  6. 6.
    Rezkalla SH, Dharmashankar KC, Abdalrahman IB, Kloner RA. No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy. J Interv Cardiol. 2010;23(5):429–36.PubMedCrossRefGoogle Scholar
  7. 7.
    Malmberg K, Rydén L, Efendic S, et al. Randomized trial of insulin-glucose infusion following by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:57–65.PubMedCrossRefGoogle Scholar
  8. 8.
    Di Carli NF, Janisse J, Grunberger G, Ager J. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol. 2003;41(8):1387–93.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Li XD, Yang YJ, Hao YC, et al. Effects of pre-procedural statin therapy on myocardial no-reflow following percutaneous coronary intervention: a meta analysis. Chin Med J. 2013;126(9):1755–60.PubMedGoogle Scholar
  10. 10.
    Pantsios C, Kapelios C, Vakrou S, et al. Effect of elevated reperfusion pressure on “no reflow” area and infarct size in a porcine model of ischemia-reperfusion. J Cardiovasc Pharmacol Ther. 2016;21(4):405–11.PubMedCrossRefGoogle Scholar
  11. 11.
    Ipek G, Onuk T, Karatas MB, et al. CHA2DS2-VASc score is a predictor of no-reflow in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous intervention. Angiology. 2016;67(9):840–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Kurtul A, Murat SN, Yarliogluez M, et al. Mild to moderate renal impairment is associated with no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. Angiology. 2015;66(7):644–51.PubMedCrossRefGoogle Scholar
  13. 13.
    Kurtul A, Yarlioglues M, Celik IE, et al. Association of lymphocyte-to-monocyte ratio with the no-reflow phenomenon in patients who underwent a primary percutaneous coronary intervention for ST-elevation myocardial infarction. Coron Artery Dis. 2015;26(8):706–12.PubMedCrossRefGoogle Scholar
  14. 14.
    Amano H, Ikeda T, Toda M, et al. Plaque composition and no-reflow phenomenon during percutaneous coronary intervention of low-echoic structures in grayscale intravascular ultrasound. Int Heart J. 2016;57(3):285–91.PubMedCrossRefGoogle Scholar
  15. 15.
    Suda A, Namiuchi S, Kawaguchi T, et al. A simple and rapid method for identification of lesions at high risk for the no-reflow phenomenon immediately before elective coronary stent implantation. Heart Vessel. 2016;31(12):1904–14.CrossRefGoogle Scholar
  16. 16.
    Grygier M, Araszkiewicz A, Lesiak M, Grajek S. Role of adenosine as an adjunct therapy in the prevention and treatment of no-reflow phenomenon in acute myocardial infarction with ST segment elevation: review of the current data. Kardiol Pol. 2013;71(2):115–20.PubMedCrossRefGoogle Scholar
  17. 17.
    Fischell TA, Maheshewari A. Current applications for nicardipine in invasive and interventional cardiology. J Invasive Cardiol. 2004;16(8):428–32.PubMedGoogle Scholar
  18. 18.
    Wang HJ, Lo PH, Lin JJ, et al. Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction. Catheter Cardiovasc Interv. 2004;63(2):171–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Johnson-Cox HA, Yang D, Ravid K. Physiological implications of adenosine receptor-mediated platelet aggregation. J Cell Physiol. 2011;226(1):46–51.CrossRefGoogle Scholar
  20. 20.
    Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of adenosine(AMISTAD) trial. J Am Coll Cardiol. 1999;34(6):1711–20.PubMedCrossRefGoogle Scholar
  21. 21.
    Ross AM, Gibbons RJ, Stone GW, AMISTAD-II Investigators, et al. A randomized, double-blinded, placebo controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol. 2005;45(11):1775–80.PubMedCrossRefGoogle Scholar
  22. 22.
    Vijayalakshmi K, Whittaker VJ, Kunadian B, et al. Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart. 2006;92(9):1278–84.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Niccoli G, Rigattieri S, De Vita MR, et al. Open label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the intervention of microvascular obstruction in acute myocardial infarction: the REOPEN-AMI study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction). JACC Cardiovasc Interv. 2013;6(6):580–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Navarese EP, Buffon A, Andreotti F, et al. Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials. Atherosclerosis. 2012;222(1):1–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Gao Q, Yang B, Guo Y, Zheng F. Efficacy of adenosine in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a PRISMA-compliant meta-analysis. Medicine (Baltimore). 2015;94(32):e1279.CrossRefGoogle Scholar
  26. 26.
    Su Q, Nyi TS, Li L. Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction. Cochrane Database Syst Rev. 2015;5:CD009503.Google Scholar
  27. 27.
    Polimeni A, De Rosa S, Sabatino J, et al. Impact of intracoronary adenosine administration during primary PCI: a meta-analysis. Int J Cardiol. 2016;203:1032–41.PubMedCrossRefGoogle Scholar
  28. 28.
    Bulluck H, Sirker A, Loke YK, et al. Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: an updated meta-analysis of randomized controlled trials. Int J Cardiol. 2016;202:228–37.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Nazir SA, McCann GP, Greenwood JP. Strategies to attenuate micro-vascular obstruction during P-PCI: the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial. Eur Heart J. 2016;37:1910–9.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Yetgin T, Uitterdijk A, te Lintel HM, et al. Limitation of infarct size and no-reflow by intracoronary adenosine depends critically on dose and duration. JACC Cardiovasc Interv. 2015;8(15):1990–9.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Su Q, Li L, Liu Y. Short-term effect of verapamil on coronary no-reflow associated with percutaneous coronary intervention in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Cardiol. 2013;36(8):E11–6.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Kaplan BM, Benzuly KH, Kinn JW, et al. Treatment of no-reflow in degenerated saphenous vein graft intervention: comparison of intracoronary verapamil and nitroglycerin. Catheter Cardiovasc Diagn. 1996;39(2):113–8.CrossRefGoogle Scholar
  33. 33.
    Wang L, Cheng Z, Gu Y, Peng D. Short-term effects of verapamil and diltiazem in the treatment of no reflow phenomenon: a meta-analysis of randomized controlled trials. Biomed Res Int. 2015;2015:382086.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Fischell TA, Haller S, Pulukurthy S, Virk IS. Nicardipine and adenosine “flush cocktail” to prevent no-reflow during rotational atherectomy. Cardiovasc Revasc Med. 2008;9(4):224–8.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Fischell TA, Subraya RG, Ashraf K, et al. “Pharmacologic” distal protection sing prophylactic, intragraft nicardipine to prevent no-reflow and non-Q wave myocardial infarction during elective saphenous vein graft intervention. J Invasive Cardiol. 2007;19(2):58–62.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Lambert CR, Pepine CJ. Effects of intravenous and intracoronary nicardipine. Am J Cardiol. 1989;64(15):8H–15H.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Ferrari R. The role of mitochondria in ischemic heart disease. J Cardiovasc Pharmacol. 1996;28:1–10.Google Scholar
  38. 38.
    Wu M, Huang Z, Xie H, Zhou Z. Nicorandil in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis. PLoS One. 2013;8(10):e78231.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Parham WA, Bouhasin A, Ciaramita JP, et al. Coronary hyperemic dose responses of intracoronary sodium nitroprusside. Circulation. 2004;109(10):1236–43.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Kobatake R, Sato T, Fujiwara Y, et al. Comparison of the effects of nitroprusside versus nicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction. Heart Vessel. 2011;26(4):379–84.CrossRefGoogle Scholar
  41. 41.
    Parikh KH, Chag MC, Shah KJ, et al. Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no-reflow during angioplasty: a clinical scenario of ischemic preconditioning. Can J Physiol Pharmacol. 2007;85(3–4):476–82.PubMedCrossRefGoogle Scholar
  42. 42.
    Su Q, Li L, Naing KA, Sun Y. Safety and effectiveness of nitroprusside in preventing no-reflow during percutaneous coronary intervention: a systematic review. Cell Biochem Biophys. 2014;68(1):201–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Zhao S, Qi G, Tian W, et al. Effect of intracoronary nitroprusside in preventing no reflow phenomenon during primary percutaneous coronary intervention: a meta-analysis. J Interv Cardiol. 2014;27(4):356–64.PubMedCrossRefGoogle Scholar
  44. 44.
    Amit G, Cafri C, Yaroslavtsev S, et al. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am Heart J. 2006;152(5):887.PubMedCrossRefGoogle Scholar
  45. 45.
    Poupko JM, Baskin SI, Moore E. The pharmacological properties of anisodamine. J Appl Toxicol. 2007;27(2):116–21.PubMedCrossRefGoogle Scholar
  46. 46.
    Niu X, Zhang J, Bai M, et al. Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis. BMC Cardiovasc Disord. 2018;18(1):3.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Ibanez B, James S, Agewall S, ESC Scientific Document Group, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77.CrossRefGoogle Scholar
  48. 48.
    Roffi M, Patrono C, Collet JP, ESC Scientific Document Group, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315.PubMedCrossRefGoogle Scholar
  49. 49.
    Thiele H, Wöhrle J, Hambrecht R, et al. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial. Lancet. 2012;379(9819):923–31.PubMedCrossRefGoogle Scholar
  50. 50.
    Kirma C, Erkol A, Pala S, et al. Intracoronary bolus-only compared with intravenous bolus plus infusion of tirofiban application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Catheter Cardiovasc Interv. 2012;79(1):59–67.PubMedCrossRefGoogle Scholar
  51. 51.
    Sun B, Liu Z, Yin H, et al. Intralesional versus intracoronary administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention in patients with acute coronary syndromes: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017;96(40):e8223.CrossRefGoogle Scholar
  52. 52.
    Potdar A, Sharma S. The ‘MAP strategy’ (maximum aspiration of atherothrombus and adjunctive glycoprotein IIb/IIIa inhibitor utilization combined with prolonged inflation of balloon/stent) for preventing no-reflow in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a retrospective analysis of seventy-one cases. Indian Heart J. 2015;67(Suppl 3):S43–6.PubMedCrossRefGoogle Scholar
  53. 53.
    Chen WR, Tian F, Chen YD, et al. Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction. Int J Cardiol. 2016;208:109–14.PubMedCrossRefGoogle Scholar
  54. 54.
    Agarwal SK, Agarwal S. Role of intracoronary fibrinolytic therapy in contemporary PCI practice. Cardiovasc Revasc Med. 2018.  https://doi.org/10.1016/j.carrev.2018.11.021.
  55. 55.
    Sezer M, Oflaz H, Gören T, et al. Intracoronary streptokinase after primary percutaneous coronary intervention. N Engl J. 2007;356(18):1823–34.CrossRefGoogle Scholar
  56. 56.
    Sezer M, Çimen A, Aslanger E, et al. Effect of intracoronary streptokinase administered immediately after primary percutaneous coronary intervention on long-term left ventricular infarct size, volumes, and function. J Am Coll Cardiol. 2009;54(12):1065–71.PubMedCrossRefGoogle Scholar
  57. 57.
    Geng W, Zhang Q, Liu J, et al. A randomized study of prourokinase during primary percutaneous coronary intervention in acute ST segment elevation myocardial infarction. J Interv Cardiol. 2018;31(2):136–43.PubMedCrossRefGoogle Scholar
  58. 58.
    Sun B, Liu J, Yin H, et al. Delayed vs. immediate stenting in STEMI with a high thrombus burden: a systematic review and meta-analysis. Herz. 2018.  https://doi.org/10.1007/s00059-018-4699-x.
  59. 59.
    Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation. 2005;112(14):2143–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Grube E, Schofer JJ, Webb J, et al. Evaluation of a balloon occlusion and aspiration system for protection from distal embolization during stenting in saphenous vein grafts. Am J Cardiol. 2002;89(8):941–5.PubMedCrossRefGoogle Scholar
  61. 61.
    Grube E, Gerckens U, Yeung AC, et al. Prevention of distal embolisation during coronary angioplasty in saphenous vein grafts and native vessels using porous filter protection. Circulation. 2001;104(20):2436–41.PubMedCrossRefGoogle Scholar
  62. 62.
    Gick M, Jander N, Bestehorn HP, et al. Randomized evaluation of the effects of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myocardial infarction with and without st-segment elevation. Circulation. 2005;112(10):1462–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Chollet F, Tardy J, Albucher JF, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011;10(2):123–30.PubMedCrossRefGoogle Scholar
  64. 64.
    De Vita M, Burzotta F, Biondi-Zoccai GG, et al. Individual patient-data meta-analysis comparing clinical outcome in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention with or without prior thrombectomy. ATTEMPT study: a pooled Analysis of Trials on ThrombEctomy in acute Myocardial infarction based on individual PatienT data. Vasc Health Risk Manag. 2009;5(1):243–7.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Mongeon FP, Bélisle P, Joseph L, et al. Adjunctive thrombectomy for acute myocardial infarction: a bayesian meta-analysis. Circ Cardiovasc Interv. 2010;3(1):6–16.PubMedCrossRefGoogle Scholar
  66. 66.
    Awadalla H, Salloum J, Moustapha A, et al. Rheolytic thrombectomy does not prevent slow-, no-reflow during percutaneous coronary intervention in acute myocardial infarction. Int J Angiol. 2003;12(3):183–7.CrossRefGoogle Scholar
  67. 67.
    Jolly SS, James S, Džavík V, et al. Thrombus aspiration in ST-segment-elevation myocardial infarction: an individual patient meta-analysis: thrombectomy trialists collaboration. Circulation. 2017;135(2):143–52.PubMedCrossRefGoogle Scholar
  68. 68.
    Herring MJ, Dai W, Hale SL, Kloner RA. Rapid induction of hypothermia by the ThermoSuit system profoundly reduces infarct size and anatomic zone of no reflow following ischemia-reperfusion in rabbit and rat hearts. J Cardiovasc Pharmacol Ther. 2015;20(2):193–202.PubMedCrossRefGoogle Scholar
  69. 69.
    Noc M, Erlinge D, Neskovic AN. COOL AMI EU pilot trial: a multicentre, prospective, randomised controlled trial to assess cooling as an adjunctive therapy to percutaneous intervention in patients with acute myocardial infarction. EuroIntervention. 2017;13(5):e531–9.PubMedCrossRefGoogle Scholar
  70. 70.
    Mewton N, Thibault H, Roubille F, et al. Postconditioning attenuates no-reflow in STEMI patients. Basic Res Cardiol. 2013;108(6):383.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Ovize M, Baxter GF, Di Lisa F, Working Group of Cellular Biology of Heart of European Society of Cardiology, et al. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res. 2010;87(3):406–23.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Danijela Trifunovic
    • 1
    • 2
  • Jelena Dudic
    • 2
  • Natalija Gavrilovic
    • 2
  • Olivia Manfrini
    • 3
  1. 1.Department of CardiologyClinical Center of SerbiaBelgradeSerbia
  2. 2.Faculty of MedicineBelgrade UniversityBelgradeSerbia
  3. 3.Department of Experimental, Diagnostic and Specialty MedicineUniversity of BolognaBolognaItaly

Personalised recommendations